Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 183-189

  Knoefel, Lena Franziska ^a   Werle Schneider, Gisela ^a   Dally, Heike ^a   Müller, Phillip Johannes ^a   Edler, Lutz ^a   Bartsch, Helmut ^a   Tuengerthal, Siegfried ^b   Heussel, Claus Peter ^a,b   Reinmuth, Niels ^c   Thomas, Michael ^c   Risch, Angela ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Division of Radiology   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCL 2; Polymorphism; Small cell; Survival

Indexed keywords

ETOPOSIDE; IFOSFAMIDE; PLATINUM DERIVATIVE; PROTEIN BCL 2; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 78651111838     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f8a20e     Document Type: Article

References (26)

1. Christodoulou C, Skarlos DV. Treatment of small cell lung cancer. Semin Respir Crit Care Med 2005;26:333-341.
2. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22: 7414-7430.
3. Wang GQ, Gastman BR, Wieckowski E, et al. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 2001;276: 34307-34317.
4. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-876.
5. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008;14:3268-3277.
6. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008;68:2321-2328.
7. Danesi R, de Braud F, Fogli S, et al. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 2001;22: 420-426.
8. Nuckel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938°CA) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007; 109:290-297.
9. Robert J, Morvan VL, Smith D, et al. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54:171-196.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
11. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002;97:584-592.
12. Han JY, Hong EK, Choi BG, et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol 2003; 20:355-362.
13. Fennell DA. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer 2003;4:307-313.
14. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6: 2547-2555.
15. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435: 677-681.
16. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-1183.
17. Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.
18. Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64.
19. Kaiser U, Schilli M, Haag U, et al. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 1996;15:31-40.
20. Maitra A, Amirkhan RH, Saboorian MH, et al. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol 1999; 30:712-717.
21. Ilievska PB, Smickova S, Jovanovska CS, et al. Bcl-2 as a prognostic factor for survival in small-cell lung cancer. Prilozi 2009;29:281-294.
22. Bachmann HS, Otterbach F, Callies R, et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938°CA) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 2007;13:5790-5797.
23. Hirata H, Hinoda Y, Kikuno N, et al. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009;181:1907-1912.
24. Hirata H, Hinoda Y, Nakajima K, et al. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer. J Urol 2009;182: 721-727.
25. Olejniczak ET, Van Sant C, Anderson MG, et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007;5:331-339.
26. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for responseassessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-1292.